ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026
The Molecular Heterogeneity of NRAS Variants in Thyroid Nodules.
Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNRAS variants are the most common mutations in thyroid nodules with (B)ethesda III/IV cytology. This study aims to characterize co-occurring variants, molecular signatures, and hallmarks of cancer pathways in nodules with NRAS variants. STUDY
designRetrospective database analysis.
methodsThe database of nodules sent for Afirma GSC testing was analyzed for the most common NRAS hotspot mutations, co-occurring mutations, BRAF-RAS score (BRS), thyroid differentiation score (TDS), ERK expression, and activity levels of hallmarks of cancer pathways.
resultsOf 87,817 Afirma GSC-suspicious or BV/VI nodules, 12.6% had NRAS mutations. Of those, 79.7% were NRAS p.Q61R and 19.4% were NRAS p.Q61K. 421 nodules (3.8%) had co-occurring mutations, EIF1AX being the most common (1%, about twice the rate seen alone). Of 872 nodules with TERT promoter mutations (TERTp), 7.8% had concurrent NRAS + TERT mutations (more than twice the rate of TERT alone). The presence of NRAS (+/- co-mutations) was highly RAS-like on the BRS score. Hallmarks of cancer pathways analyzed across NRAS+ nodules, with TERTp profiling, revealed 2 distinct clusters: one with higher inflammatory pathway activity, and another with higher DNA repair, estrogen response, and MYC activity. The latter had a higher rate of BV/VI nodules. NRASp.Q61R was equally distributed across the 2 clusters.
conclusionNRAS p.Q61R/K comprises 99% of reported NRAS variants. TERTp is the most frequent co-mutation. Among NRAS p.Q61R/K nodules, there are 2 different clusters of samples based on the activity of hallmarks of cancer pathways. Further studies correlating these clusters with clinical and pathological outcomes are necessary.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.